HiJAKing the epigenome in leukemia and lymphoma

References

• Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293–322.
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161–170.
   PubMed Web of Science ®Google Scholar
• Ihle JN. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv Immunol. 1995;60:1–35.
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015;66:311–328.
   PubMed Web of Science ®Google Scholar
• Chen E, Staudt LM, Green AR. Janus kinase deregulation in leukemia and lymphoma. Immunity. 2012;36:529–541.
   PubMed Web of Science ®Google Scholar
• Giordanetto F, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng. 2002;15:727–737.
   PubMedGoogle Scholar
• Yamaoka K, Saharinen P, Pesu M, et al. The Janus kinases (Jaks). Genome Biol. 2004;5:253.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273–287.
   PubMed Web of Science ®Google Scholar
• Losdyck E, Hornakova T, Springuel L, et al. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities. J Biol Chem. 2015;290:29022–29034.
   PubMed Web of Science ®Google Scholar
• Brooks AJ, Dai W, O'Mara ML, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science. 2014;344:1249783.
   PubMed Web of Science ®Google Scholar
• Moraga I, Richter D, Wilmes S, et al. Instructive roles for cytokine-receptor binding parameters in determining signaling and functional potency. Sci Signal. 2015;8:ra114.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–1148.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88–92.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12:131–144.
   PubMed Web of Science ®Google Scholar
• Griffiths DS, Li J, Dawson MA, et al. LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol. 2011;13:13–21.
   PubMed Web of Science ®Google Scholar
• Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008;372:1484–1492.
   PubMed Web of Science ®Google Scholar
• Kearney L, Gonzalez De Castro D, Yeung J, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood. 2009;113:646–648.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2009;106:9414–9418.
   PubMed Web of Science ®Google Scholar
• Jeong EG, Kim MS, Nam HK, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res. 2008;14:3716–3721.
   PubMed Web of Science ®Google Scholar
• Bellanger D, Jacquemin V, Chopin M, et al. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia. 2014;28:417–419.
   PubMed Web of Science ®Google Scholar
• Flex E, Petrangeli V, Stella L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008;205:751–758.
   PubMed Web of Science ®Google Scholar
• Bains T, Heinrich MC, Loriaux MM, et al. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia. 2012;26:2144–2146.
   PubMed Web of Science ®Google Scholar
• Bouchekioua A, Scourzic L, de Wever O, et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia. 2014;28:338–348.
   PubMed Web of Science ®Google Scholar
• Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012;2:591–597.
   PubMed Web of Science ®Google Scholar
• Sakaguchi H, Okuno Y, Muramatsu H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 2013;45:937–941.
   PubMed Web of Science ®Google Scholar
• Lopez C, Bergmann AK, Paul U, et al. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. Br J Haematol. 2016;173:265–273.
   PubMed Web of Science ®Google Scholar
• Elliott NE, Cleveland SM, Grann V, et al. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood. 2011;118:3911–3921.
   PubMed Web of Science ®Google Scholar
• Sato T, Toki T, Kanezaki R, et al. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. Br J Haematol. 2008;141:681–688.
   PubMed Web of Science ®Google Scholar
• Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006;10:65–75.
   PubMed Web of Science ®Google Scholar
• Atak ZK, Gianfelici V, Hulselmans G, De Keersmaecker K, Devasia AG, Geerdens E, et al. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet. 2013;9:e1003997.
   PubMed Web of Science ®Google Scholar
• Bentz M, Werner CA, Dohner H, et al. High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma. Blood. 1996;88:1437–1444.
   PubMed Web of Science ®Google Scholar
• Bentz M, Barth TF, Bruderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosom Cancer. 2001;30:393–401.
   PubMed Web of Science ®Google Scholar
• Meier C, Hoeller S, Bourgau C, et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol. 2009;22:476–487.
   PubMed Web of Science ®Google Scholar
• Rui L, Emre NC, Kruhlak MJ, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010;18:590–605.
   PubMed Web of Science ®Google Scholar
• Joos S, Kupper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 2000;60:549–552.
   PubMed Web of Science ®Google Scholar
• Lam LT, Wright G, Davis RE, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111:3701–3713.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–862.
   PubMed Web of Science ®Google Scholar
• Kapp U, Yeh WC, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med. 1999;189:1939–1946.
   PubMed Web of Science ®Google Scholar
• Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99:618–626.
   PubMed Web of Science ®Google Scholar
• Andersson E, Schain F, Sjoberg J, et al. Interleukin-13 stimulation of the mediastinal B-cell lymphoma cell line Karpas-1106P induces a phenotype resembling the Hodgkin lymphoma cell line L1236. Exp Hematol. 2010;38:116–123.
   PubMed Web of Science ®Google Scholar
• Guiter C, Dusanter-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004;104:543–549.
   PubMed Web of Science ®Google Scholar
• Ding BB, Yu JJ, Yu RY, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008;111:1515–1523.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115–119.
   PubMed Web of Science ®Google Scholar
• Shi S, Calhoun HC, Xia F, et al. JAK signaling globally counteracts heterochromatic gene silencing. Nat Genet. 2006;38:1071–1076.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Bannister AJ, Gottgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009;461:819–822.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Foster SD, Bannister AJ, et al. Three distinct patterns of histone H3Y41 phosphorylation mark active genes. Cell Rep. 2012;2:470–477.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871–3879.
   PubMed Web of Science ®Google Scholar
• Rui L, Schmitz R, Ceribelli M, et al. Malignant pirates of the immune system. Nat Immunol. 2011;12:933–940.
   PubMed Web of Science ®Google Scholar
• Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471:377–381.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311–319.
   PubMed Web of Science ®Google Scholar
• Rui L, Drennan AC, Ceribelli M, et al. Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2016;113:E7260–E72E7.
   PubMed Web of Science ®Google Scholar
• Zhu F, Hwang B, Miyamoto S, Rui L. Nuclear import of JAK1 is mediated by a classical nls and is required for survival of diffuse large B-cell lymphoma. Mol Cancer Res. 2017;15:348–357.
   PubMed Web of Science ®Google Scholar
• Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood. 2008;111:5663–5671.
   PubMed Web of Science ®Google Scholar
• Diaz T, Navarro A, Ferrer G, et al. Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PloS One. 2011;6:e18856.
   PubMed Web of Science ®Google Scholar
• Hao Y, Chapuy B, Monti S, et al. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res. 2014;20:2674–2683.
   PubMed Web of Science ®Google Scholar
• Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009;16:487–497.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Yasothan U, Kirkpatrick P. Ruxolitinib. Nat Rev Drug Discov. 2012;11:103–104.
   PubMed Web of Science ®Google Scholar
• Hwang B, McCool K, Wan J, et al. IPO3-mediated nonclassical nuclear import of NF-kappaB essential modulator (NEMO) Drives DNA damage-dependent NF-kappaB activation. J Biol Chem. 2015;290:17967–17984.
   PubMed Web of Science ®Google Scholar
• Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J, et al. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol. Forthcoming. [cited 2016 Dec 29]. DOI:10.1038/nrclinonc.2016.205
   Web of Science ®Google Scholar
• Derenzini E, Lemoine M, Buglio D, et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J. 2011;1:e46.
   PubMed Web of Science ®Google Scholar
• Guo A, Lu P, Coffey G, Conley P, Pandey A, Wang YL. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. Oncotarget. Forthcoming. [cited 2017 Jan 10]. DOI:10.18632/oncotarget.14588
   Web of Science ®Google Scholar
• Blunt MD, Koehrer S, Dobson RC, Larrayoz M, Wilmore S, Hayman A, et al. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clinical cancer research: an official journal of the American Association for Cancer Research. 2016 Oct 03.
   Google Scholar